Vanda Pharmaceuticals (VNDA) jumps after FDA approves its motion-sickness drug Nereus (tradipitant)

What happened

On December 30–31, 2025, the FDA approved Vanda’s Nereus (tradipitant) to prevent vomiting induced by motion. It’s the first new FDA-approved treatment for motion-induced vomiting in over 40 years, and Vanda says it plans to launch in the coming months.

Why the market cares

1. A brand-new FDA label creates a near-term commercial story (launch, pricing, payer coverage, distribution).

2. It also validates tradipitant as a platform asset, with Vanda pursuing other nausea/vomiting settings, including GLP-1-related nausea.

3. It re-opens a category dominated by older OTC and patch options (Dramamine, Bonine, scopolamine patch).

Winners

FDA Catalyst Small/Mid-Cap Bi ...